We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Groundbreaking POCT Device Detects UTI Causing Bacteria in Five Minutes

By HospiMedica International staff writers
Posted on 17 Aug 2023

Urinary tract infection (UTI) is a prevalent health concern globally, particularly affecting women during pregnancy. More...

Various bacteria can cause UTIs, leading to symptoms like a burning sensation during urination and an increased need to urinate. If the infection spreads to the kidneys, it can result in serious complications. Conventionally, urine cultures are used to detect and identify the specific bacteria responsible, a process that takes at least two days. This delay can cause suffering for the patient and even be fatal in some instances. In rural areas, the problem is exacerbated by inadequate infrastructure, high testing costs, and extended testing time, leading to many UTIs going undetected.

Researchers at the Indian Institute of Technology Guwahati (IIT Guwahati, Assam, India) have made a significant breakthrough by creating a 3D printed photodetector device that can identify and quantify a UTI-causing bacteria known as Klebsiella pneumoniae within five minutes from a urine sample. This capability is highly significant, as Klebsiella pneumoniae is not only a common cause of UTI but is also linked to pneumonia and soft tissue infections.

To create the prototype, the researchers utilized gold nanoparticles combined with specially engineered aptamers. An aptamer is similar to a 3D puzzle piece that fits only on the surface of specific bacteria. As a result, the gold nanoparticles get agglomerated on the surface of the target bacteria, generating a unique signature detectable by a UV-visible spectrophotometer. The device’s biosensor identifies changes in light intensity when the aptamer-gold nanoparticles-bacteria come together. The aptamer and bacteria combine instantly to result in rapid detection. Importantly, this innovative prototype is not only specific to Klebsiella pneumoniae but is also adaptable to different types of bacteria, offering great potential for primary healthcare. Furthermore, the cost-effective nature of the device could make it particularly beneficial in rural areas where UTIs frequently remain undiagnosed due to limited access to testing facilities.

Related Links:
IIT Guwahati 


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Electric Bed
DIXION Intensive Care Bed
New
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.